Hospital Universitario Hm Sanchinarro — Clinical Trial Site

446 Registered trials

178 Currently recruiting

Organisation

Hospital Universitario Hm Sanchinarro

Location

Madrid, Spain

Identifier

ORG-100041243

Address

Calle Ona 10, 28050, Spain

Departments

-
#03401: START
#1401: Oncología
#2201: Oncología médica
#2201: START Madrid-HM CIOCC Early Phase Program
#2409: Oncología
#3004:Oncology
#3032403: N/A
#3102:Oncología médica
#3301: START Madrid- Centro Integral Oncologico Clara Campal
#40615:Memory Disorders Unit
#7001:Medical Oncology
034-04: Oncology
2001: Oncología
3304: Oncologia
602 : Oncología Médica
7000: Oncología médica
7001: CIOCC Phase I Unit
803: Servicio de Oncología Médica, Sótano -1
9003: Hematología
9400:Oncología Médica
Centro Integral Oncológico Clara Campal
Centro Integral Oncológico Clara Campal (CIOCC)
Centro Integral Oncológico Clara Campal (CIOCC) Phase I Trials Unit
Centro Integral Oncologico Clara Campal CIOCC
Centro Integral Oncológico Clara Campall
Centro Integral Oncológico Clara Campall (CIOCC) Phase I trials unit
CIOCC
CIOCC Early Phase Program
CIOCC Phase I trials
CIOCC- Medical Oncology- Digestive Unit
CIOCC, Ensayos Clínicos planta S-1
Clinical Investigator Early Phase Trials Unit
Dermatology
Early phase drug development
Ensayos Clinicos
Ensayos Clínicos Fases I START
ESP020: Oncología
Head and Neck and Cancer, Gastrointestinal Cancer Unit
Hematología
Hematología y Hemoterapia
Hematologist
Hematology
Hematology and Hemotherapy
Hematology and Hemotherapy Medical Oncology
Hematology Unit
Infecciosas
Internal Medicine
MEDICAL ONCOLOGIST
Medical Oncology
Medical Oncology Department
Medical Oncology Service
Medical Oncology/phase 1 trials unit
Medicina Nuclear
N/A
Neumología
Neurology
Neurooncología
Not applicable
Nuclear Medicine
Onccology Department
Oncologfa, Ensayos Clfnicos Fases I START Madrid-CIOCC
Oncología
Oncología - START MADRID
Oncología Médica
Oncologia Meidica
Oncología Radioterápica
Oncología, Unidad de Fase I START Madrid-CIOCC
Oncology
Oncology Department
Oncology Medicine
Oncology Phase I trials unit
Oncology Phase I Unit
Oncology Service
Oncology, Clínical Trials Phase I START Madrid-CIOCC Centro Integral Oncologico Clara Campal
Oncology, Clínical Trials Phase I START Madrid-CIOCC Centro Integral Oncologico Clara Campal
Pediatrics
Phase 1 Unit, 3rd floor
Phase I Trials
Phase I trials unit
Phase I Unit
Phase I- START MADRID CIOCC Unit
Physican
Pneumology
Pneumonology
Pulmonology
Rheumatology
Servicio de Hematologia
Servicio de Hematologia y Oncohematologia
Servicio de Neurología
Servicio de Oncología
Servicio de Oncología Médica
Servicio Hematología y Hemoterapia / Oncología, Ensayos Clínicos Fases I START-Madrid-CIOCC
START
Start - Centro Integral Oncológico Clara Campal
START Early Phase Clinical Trial Program
START Madrid
START Madrid - CIOCC
START Madrid – CIOCC
START Madrid CIOCCHM Sanchinarro Hospital Phase I trials Unit
Start Madrid Sanchinarro
START Madrid-CIOCC
START Madrid-CIOCC (Unidad de Ensayos Fase 1)
START Madrid-CIOCC Phase I Unit
START Madrid-HM CIOCC
START Madrid-HM CIOCC Early Phase Program
START-Madrid-CIOCC
Thoracic Oncology
Unidad Central de Ensayos Clinicos
Unidad de Ensayos Clínicos START Madrid # CIOCC
Unidad de Ensayos Fases I
Unidad Fases I Star
Urology

Clinical trials at this site (446)

Search interface

Phase 1, open-label, multicenter, dose escalation study of SRG-1505 as monotherapy in subjects with mature b-cell malignancies Recruiting

2023-505204-34-00 Mature B-Cell Neoplasm, Non-Hodgkin Lymphoma, Diffuse l 1 2024-12-30
A study to test long-term treatment with brigimadlin in people with solid tumours who took part in a previous study with this medicine Recruiting

2024-514177-21-00 Solid tumours 4 2024-12-02
A Study of ZL-1310 in Patients with Small Cell Lung Cancer to Find a Suitable Dose and to Test How Different Doses of ZL-1310 are Tolerated … Recruiting

2024-514446-36-00 Small Cell Lung Cancer 1 2024-11-21
A first-in-human study of PARP1 selective inhibitor, IMP1734, in patients with advanced solid tumors. Recruiting

2023-509230-19-00 Advance solid tumors 7 2024-11-14
A study to test if different doses of D3S-001 used on its own or in combination with other anti-cancer medicines is safe and tolerable in pe… Recruiting

2023-508517-16-00 Advanced Solid Tumors with a KRAS p.G12C Mutation 7 2024-11-10
Phase II Study of Avelumab plus chemotherapy for patients with resectable Gastric cancer (GC) or Gastroesophageal Junction cancer (GEJC). Mo… Recruiting

2024-516777-77-00 Resectable Gastric cancer (GC) or Gastroesophageal Junc 4 2024-10-31
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants with Advanced Solid Malignancies Recruiting

2024-511453-22-00 Participants with Advanced Solid Malignancies 1 2024-10-28
Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects wi… Recruiting

2023-509334-19-00 gastro-enteropancreatic neuroendocrine tumors (GEP-NETs 5 2024-10-17
Treatment with darolutamide +/- radiation therapy for patients with a castration resistant cancer and metastases detected by functional imag… Recruiting

2023-507482-26-00 Castrate-resistant prostate cancer with oligometastases 5 2024-10-04
A Study to Evaluate ARV-393 in Adult Participants with Advanced Non-Hodgkin’s Lymphoma Recruiting

2023-510136-36-00 Advanced Non-Hodgkin’s Lymphoma 1 2024-09-27
A clinical trial to learn about the safety and effects of STX-241, a new oral anticancer drug for the treatment of patients with advanced lu… Recruiting

2023-510203-21-00 locally advanced or metastatic non-small cell lung canc 7 2024-09-24
Phase 1 Study of PYX-201 in Solid Tumors Recruiting

2023-509687-14-00 Advanced solid tumors 1 2024-08-29
First-in-Human Study of OKI-219 Alone and in Combination with Other Therapies in Patients with Solid Tumors / Breast Cancer Recruiting

2023-508435-31-00 Advanced Solid Tumors, Advanced Breast Cancer 1 2024-08-09
A Phase 1, Open-Label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preli… Recruiting

2023-506199-28-00 Dose escalation: Advanced Solid Tumors Dose Expansion: 1 2024-08-05
An open-label, phase I/II study of T3P-Y058-739, a genetically-modified strain of the bacterium Yersinia enterocolitica, in patients with ad… Recruiting

2023-504199-19-00 Solid Tumours 7 2024-06-26
A Phase 1 study of JNJ-87704916, a tumor-targeting virus, injected into tumor for advanced cancer Recruiting

2023-506495-27-00 Advanced solid tumors 1 2024-06-18
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX versus mFOLFIRINOX Alone in Patients wit… Recruiting

2022-502404-73-00 Pancreatic ductal adenocarcinoma 4 2024-06-03
Phase 1, First-in-Human Study to Assess the Safety, Tolerability and Anti-tumor Activity of CDR404 in HLA-A*02:01 Participants with MAGE-A4 … Recruiting

2023-508808-38-00 Solid tumors 1 2024-05-29
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation (PYNNACLE) Recruiting

2023-504251-27-00 Locally Advanced or Metastatic Solid Tumors Harboring a 7 2024-05-27
C1071032 - MAGNETISMM-32 A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMAL… Recruiting

2023-507871-23-00 Relapsed/Refractory Multiple Myeloma 5 2024-05-27
A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician’s Ch… Recruiting

2023-505660-11-00 Cholangiocarcinoma (LTT, 26.0) 5 2024-04-24
A trial to learn if AZD5335 alone and in combination with other treatments is safe and effective and how it moves through the body in people… Recruiting

2022-502576-23-00 Platinum-resistant recurrent (PRR) ovarian cancer, Plat 1 2024-04-17
STUDY OF OP-1250 ADMINSTERED AS MONOTHERAPY AND COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2– ADVANCED OR METASTATIC BREAST C… Recruiting

2023-505871-63-00 ER+, HER2- metastatic breast cancer following endocrine 5 2024-04-08
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting

2023-504031-41-00 ER+/HER2- Early Breast Cancer 5 2024-03-25